登录 注册
当前位置: 首页 > 药物分子靶点 反馈纠错 帮助中心
药智数据企业版注册数据库:增设了"联合申报"、"临床试验默认许可日期"等搜索条件,让搜索页面纬度更加全面,还有热点搜索和高级条件组合检索等检索功能 等你来体验!



药物名称 分子靶点 ATC编码 适应症
Cefroxadine Penicillin-binding protein 1B J01DB11 Was used for the treatment of bacterial infections.
Clobazam GABA-A receptor (anion channel) (Protein Group) N05BA09 For treatment and management of epilepsy and seizures associated with Lennox-Gastaut syndrome, a difficult-to-treat form of childhood epilepsy.
Isopropamide Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4 A03CA01 For the treatment of a wide range of gastrointestinal disorders, including such conditions as peptic ulcer, gastritis, hyperchlorhydria, functional diarrhea, irritable or spastic colon, pyloroduodenal irritability, pylorospasm, acute nonspecific gastroenteritis, biliary dyskinesia and chronic cholelithiasis, duodenitis, gastrointestinal spasm; it may also be used to treat genitourinary spasm.
Methazolamide Carbonic anhydrase 1;Carbonic anhydrase 2;Carbonic anhydrase 4;Carbonic anhydrase 7;Carbonic anhydrase 3 S01EC05 For treatment of chronic open-angle glaucoma and acute angle-closure glaucoma
Pranlukast C-X-C chemokine receptor type 4 R03DC02 Used as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists.
Tazarotene Carcinoembryonic antigen-related cell adhesion molecule 5 D05AX05 Used to treat psoriasis, acne and sun damaged skin (photodamage).
Tiapride T-cell-specific surface glycoprotein CD28 N05AL03 Tiapride is indicated for the treatment of a variety of neurological and psychiatric disorders including dyskinesia, alcohol withdrawal syndrome, negative symptoms of psychosis, and agitation and aggression in the elderly.
Acetylcarnitine Solute carrier family 22 member 21;Solute carrier family 22 member 5 N06BX12 Acetylcarnitine is not approved for any indication in the United states and Canada, but it is approved and indicated in Italy for cerebrovascular disorders, mental function disorders, peripheral nerve disorders, diabetic neuropathy, and nutritional supplementation; Portugal for mental function disorders; Argentina for cerebral vasculopathy, nutritional supplementation, and peripheral neuropathy; Chile for dementia; Philippines for cerebrovascular disorders and mental function disorders; Australia for nutritional supplementation; and India for nutritional supplementation to increase sperm count. Acetylcarnitine also has several potential therapeutic indications for which it is still being investigated: in Norway, acetylcarnitine is in a phase IV trial for prophylactic treatment of migraines; in Italy acetylcarnitine is in a phase II trial for use in patients with type 2 Diabetes Mellitus, a phase III trial for alleviating fatigue in patients with chronic hepatitis C, and for use in patients with Minimal Hepatic Encephalopathy; in the United States acetylcarnitine is in a phase II trial for the neurodegenerative disorder Progressive Supranuclear Palsy, a phase II and III trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy, a phase I and II trial for treating patients in septic shock, a phase II trial for bipolar depression, a phase II trial to reduce oxidative stress in patients with Sickle Cell disease, a phase I and II trial for chronic fatigue syndrome, and a study for preventing nerve damage in HIV patients; in China acetylcarnitine is in a phase III trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy; in the United Kingdom acetylcarnitine is being investigated for preventing nerve damage in HIV patients; and in Israel acetylcarnitine is being studied for the treatment of male infertility.
Degarelix Gonadotropin-releasing hormone receptor L02BX02 Degaralix is used for the management of advanced prostate cancer.
Isoprenaline Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;Beta-3 adrenergic receptor;Mitogen-activated protein kinase 1;Phosphatidylinositol 3-kinase regulatory subunit alpha;Phosphatidylinositol 3-kinase regulatory subunit beta;Phosphatidylinositol 3-kinase C01CA02 For the treatment of mild or transient episodes of heart block that do not require electric shock or pacemaker therapy also used in management of asthma and chronic bronchitis
Metharbital Gamma-aminobutyric acid receptor subunit alpha-1;Gamma-aminobutyric acid receptor subunit alpha-2;Gamma-aminobutyric acid receptor subunit alpha-3;Gamma-aminobutyric acid receptor subunit alpha-4;Gamma-aminobutyric acid receptor subunit alpha-5;Gamma-amin N03AA30 Metharbital is used for the treatment of epilepsy.
Omacetaxine mepesuccinate 50S ribosomal protein L2;60S ribosomal protein L3 L01XX40 Used in patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML.
Romidepsin Tumor necrosis factor ligand superfamily member 12 L01XX39 For the treatment of cutaneous T-cell lymphoma (CTCL) or/and peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior systemic therapy. These indications are based on response rate. Clinical benefit such as improvement in overall survival has not been demonstrated.
Technetium Tc-99m oxidronate Neuronal acetylcholine receptor; alpha3/beta4;Neuronal acetylcholine receptor; alpha4/beta2 V09BA01 Technetium Tc-99m oxidronate is indicated in adult and pediatric patients to be used in skeletal imaging for diagnosis of areas that can present altered osteogenesis. When administered intravenously, it is able to generate a clear image of the bones which allows the physician to diagnose any bone problem.[6] It is important to point out that this drug has to be manipulated only under the service of a nuclear specialist.[5] The approved indications for a bone scan are 1) visualization of tumor metastasis in bone, 2) osteomyelitis, 3) fracture, 4) stress fracture, 5) avascular necrosis, 6) osteoporosis and 7) prosthetic joint evaluation. From all the major indications, the detection of a metastatic disease is the most common because it presents a 95% of sensitivity and lesion detection can be done 6 months earlier than with X-ray studies.[4]
Abetimus Bifunctional tail protein L04AA22 Investigated for use/treatment in kidney disease and systemic lupus erythematosus.
Acetylcholine Acetylcholinesterase;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Neuronal acetylcholine receptor subunit alpha-7 S01EB09 Used to obtain miosis of the iris in seconds after delivery of the lens in cataract surgery, in penetrating keratoplasty, iridectomy and other anterior segment surgery where rapid miosis may be required.
Ceftizoxime MecA PBP2' (penicillin binding protein 2');Penicillin-binding protein 1A;Penicillin-binding protein 1B;Peptidoglycan synthase FtsI J01DD07 For the treatment of infections due to susceptible strains of microorganisms.
Clemastine Histamine H1 receptor D04AA14 For the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus and acrimation. Also for the management of mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Used as self-medication for temporary relief of symptoms associated with the common cold.
Delavirdine Reverse transcriptase/RNaseH J05AG02 For the treatment of HIV-1 infection in combination with appropriate antiretroviral agents when therapy is warranted
Flunarizine Voltage-dependent T-type calcium channel subunit alpha-1G;Voltage-dependent T-type calcium channel subunit alpha-1H;Voltage-dependent T-type calcium channel subunit alpha-1I;Histamine H1 receptor;Calmodulin N07CA03 Used in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.